Table 1.
Patient and tumour/treatment characteristics
| Characteristics | n (%) |
|---|---|
| Gender | |
| Male | 44 (57.9) |
| Female | 32 (42.1) |
| Age (years), median (range) | 60 (31–89) |
| Metachronous OM | 76 (100) |
| Synchronous OM | 0 (0) |
| Treatment of local recurrence | 12 (15.8) |
| Regional lymphadenopathy | 14 (18.4) |
| Distant metastases | 50 (65.8) |
| Concomitant endocrine treatment | 13 (17.1) |
| Treatment site | |
| Lymph nodea | 32 (42.1) |
| Bone | 9 (11.8) |
| Spine | 13 (17.1) |
| Head + neck | 6 (7.9) |
| Liver | 5 (6.6) |
| Pre-sacral | 6 (7.9) |
| Abdominal | 5 (6.6) |
| Primary tumour site | |
| Colorectal/anal | 29 (38.2) |
| Breast | 14 (18.4) |
| Prostate | 9 (11.8) |
| Head + neck | 6 (7.9) |
| Urology (non-prostate) | |
| Bladder | 1 (1.3) |
| Ureter | 2 (2.6) |
| Renal | 5 (6.6) |
| Testicular | 1 (1.3) |
| Other | |
| Upper GI | 2 (2.6) |
| Gynae | 3 (3.9) |
| Lung | 2 (2.6) |
| Melanoma | 2 (2.6) |
GI, gastrointestinal; OM, oligometastases.
a
3 were abdominal lymphadenopathy (primary tumour site included 1 testicular and 2 colorectal), 16 were aortic lymphadenopathy (primary tumour site included 9 colorectal, 1 renal, 1 gynaecological, 1 breast, 2 prostate, 1 gallbladder and 1 melanoma), 2 were neck lymphadenopathy (primary tumour site included breast and lung) and 11 were pelvic lymphadenopathy (primary tumour site included 8 colorectal, 1 gynaecological and 2 prostate).